|Day Low/High||109.19 / 109.96|
|52 Wk Low/High||91.11 / 119.24|
If China talks fail and Uber deal gets botched, then following market dip could mean time to buy.
Buffett and Munger have some questions to answer, some situations to ponder, and probably a more concerned public than in the past to deal with.
Smaller banks such as Valley are staring down some headwinds.
Pinterest isn't exactly bringing the power to the people.
Focus on defense, as news headlines on the Mueller Report and discussion of 'Medicare For All' make stock picking tough.
The biggest negative in the market Wednesday was that the gap-up open was sold very aggressively.
JPM's IV is sitting at a 52-week low, while the stock looks pretty strong.
Both big banks are modestly valued with hefty dividend yields.
It has become almost too onerous to own something that could be in Amazon's crosshairs.
Citigroup's stock move could be described as unenthusiastic, reflecting how many feel about its first quarter earnings results.
Should the global economic picture improve this stock will pop more than most.
A look at the financials as earnings season kicks into high gear.
Citigroup investors may need more information before calling the earnings beat a buying opportunity.
What I see from 10,000 feet above... in the age of suddenly profitable fuel as cargo, are the railroads.
The reaction to earnings will tell us quite a bit about this market.
The U.S. economy is doing okay, but not great, and you can see that in a number of sectors.
We now have a Goldilocks' market environment.
We never thought, 24 hours ago, that it could possibly be this good.
With the price of crude higher (+$0.70), the yield on the 10-year U.S. note up by five basis points (to yield 2.56%) and conspicuous strength in industrials ( and +$3) and financials ( , and ), the tape has a growthy tone to it today.
With the averages skewed towards strength in JP Morgan , Boeing and Disney , I guess it's not surprising that breadth isn't even 2-1 positive. (1860 advancing/1050 declining).
It is one of those markets that look very good from the outside but much more difficult to trade once you dig in.
Here are updates on small biotech/biopharma names I have profiled before.
A combination of good economic news and friendly central banks creates a positive environment and leaves bears frustrated.
There are several metrics that will be measured across all of the major banks that analysts and investors alike must take into account.